TNGX
Tango Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$22.72
+0.84%Next report
Analyst consensus
- Next report date
- Nov 3, 2026
- EPS estimate
- -$0.35
- Revenue estimate
- $3.3M
Latest reported
- Last report date
- Aug 10, 2026
- EPS actual
- -$0.37
- EPS estimate
- -$0.32
- Revenue actual
- —
- Revenue estimate
- $1.6M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 3
- EPS misses (12Q)
- 4
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- +298.1%
- Revenue beats (12Q)
- 2
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $52
- PT range
- $35 – $68
- Analysts
- 3
3 Buy0 Hold0 Sell
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 10, 2026 | -$0.32 | -$0.37 | Miss -16.64% | — |
| May 13, 2026 | -$0.32 | -$0.32 | In line | — |
| Mar 5, 2026 | -$0.32 | -$0.29 | Beat 8.86% | — |
| Nov 4, 2025 | $0.01 | $0.13 | Beat 1200.00% | — |
| Feb 27, 2025 | -$0.32 | -$0.35 | Miss -9.37% | $4.1M |
| Mar 18, 2024 | -$0.28 | -$0.32 | Miss -14.29% | $5.4M |
| Nov 10, 2022 | -$0.32 | -$0.33 | Miss -3.13% | $6.9M |
| Aug 10, 2022 | -$0.33 | -$0.28 | Beat 15.15% | $5.8M |
| Aug 6, 2021 | — | -$0.05 | — | $18.2M |
| Mar 31, 2021 | — | -$0.42 | — | $9.1M |
| Nov 13, 2020 | — | -$0.31 | — | $11.3M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 3, 2026